Table 2.
Clinical diagnoses and reasons for requesting the anti‐Ro60 test
| Anti‐Ro60low (n, %) | Anti‐Ro60high (n, %) | P‐value | |
|---|---|---|---|
| Systemic autoimmune rheumatic disease | 35 (58·3) | 53 (62·4) | 0·730 |
| Sjögren’s syndrome | 7 (11·7) | 19 (22·4) | 0·125 |
| SLE | 15 (25·0) | 20 (23·5) | 0·846 |
| Rheumatoid arthritis | 4 (6·7) | 3 (3·5) | 0·448 |
| Mixed CTD | 4 (6·7) | 1 (1·2) | 0·160 |
| Undifferentiated CTD | 4 (6·7) | 7 (8·2) | 0·763 |
| Systemic sclerosis | 1 (1·7) | 2 (2·4) | 1·000 |
| Neonatal lupus erythematosus | 0 (0) | 1 (1·2) | 1·000 |
| Autoimmune phenomena, e.g. Raynaud’s phenomenon | 11 (18·3) | 9 (10·6) | 0·224 |
| Previous abnormal investigations, e.g. raised ANA | 2 (3·3) | 3 (3·5) | 1·000 |
| Haematological manifestations e.g. neutropaenia | 3 (5·0) | 4 (4·7) | 0·692 |
| Polyarthralgias/arthritis | 5 (8·3) | 3 (3·5) | 0·276 |
| Miscellaneous conditions | 4 (6·7) | 13 (15·3) | 0·125 |
| Total | 60 | 85 |
SLE = systemic lupus erythematosus; CTD = connective tissue disease; ANA = anti‐nuclear antibody.